Summary
Global Markets Direct’s, ‘Neisseria gonorrhoeae Infections - Pipeline Review, H2 2016’, provides an overview of the Neisseria gonorrhoeae Infections pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Neisseria gonorrhoeae Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Neisseria gonorrhoeae Infections and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Neisseria gonorrhoeae Infections
- The report reviews pipeline therapeutics for Neisseria gonorrhoeae Infections by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Neisseria gonorrhoeae Infections therapeutics and enlists all their major and minor projects
- The report assesses Neisseria gonorrhoeae Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Neisseria gonorrhoeae Infections
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Neisseria gonorrhoeae Infections
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Neisseria gonorrhoeae Infections pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
Allergan Plc
BioDiem Ltd
Biolytics Pharma
Debiopharm International SA
F. Hoffmann-La Roche Ltd.
GlaxoSmithKline Plc
Merck & Co., Inc.
Paratek Pharmaceuticals, Inc.
Recce Pty Ltd
Redx Pharma Plc
Sarepta Therapeutics, Inc.
Sumitomo Dainippon Pharma Co., Ltd
'
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Neisseria gonorrhoeae Infections Overview 8
Therapeutics Development 9
Pipeline Products for Neisseria gonorrhoeae Infections - Overview 9
Pipeline Products for Neisseria gonorrhoeae Infections - Comparative Analysis 10
Neisseria gonorrhoeae Infections - Therapeutics under Development by Companies 11
Neisseria gonorrhoeae Infections - Therapeutics under Investigation by Universities/Institutes 12
Neisseria gonorrhoeae Infections - Pipeline Products Glance 13
Late Stage Products 13
Clinical Stage Products 14
Early Stage Products 15
Neisseria gonorrhoeae Infections - Products under Development by Companies 16
Neisseria gonorrhoeae Infections - Products under Investigation by Universities/Institutes 17
Neisseria gonorrhoeae Infections - Companies Involved in Therapeutics Development 18
Allergan Plc 18
BioDiem Ltd 19
Biolytics Pharma 20
Debiopharm International SA 21
F. Hoffmann-La Roche Ltd. 22
GlaxoSmithKline Plc 23
Merck & Co., Inc. 24
Paratek Pharmaceuticals, Inc. 25
Recce Pty Ltd 26
Redx Pharma Plc 27
Sarepta Therapeutics, Inc. 28
Sumitomo Dainippon Pharma Co., Ltd. 29
Neisseria gonorrhoeae Infections - Therapeutics Assessment 30
Assessment by Monotherapy Products 30
Assessment by Target 31
Assessment by Mechanism of Action 33
Assessment by Route of Administration 35
Assessment by Molecule Type 37
Drug Profiles 39
Antisense Oligonucleotide for Drug Resistant Neisseria Gonorrhoeae Infections - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
BDM-I - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
Biologic for Neisseria Gonorrhoeae Infection - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
dalbavancin - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
Debio-1453 - Drug Profile 53
Product Description 53
Mechanism Of Action 53
R&D Progress 53
edodekin alfa SR - Drug Profile 54
Product Description 54
Mechanism Of Action 54
R&D Progress 54
gepotidacin mesylate - Drug Profile 55
Product Description 55
Mechanism Of Action 55
R&D Progress 55
Neisseria gonorrhoeae (virus like particle) vaccine - Drug Profile 57
Product Description 57
Mechanism Of Action 57
R&D Progress 57
Neisseria gonorrhoeae vaccine - Drug Profile 58
Product Description 58
Mechanism Of Action 58
R&D Progress 58
omadacycline tosylate - Drug Profile 59
Product Description 59
Mechanism Of Action 59
R&D Progress 59
Recombinant Protein for Neisseria gonorrhoeae Infections - Drug Profile 65
Product Description 65
Mechanism Of Action 65
R&D Progress 65
SM-295291 - Drug Profile 66
Product Description 66
Mechanism Of Action 66
R&D Progress 66
SM-369926 - Drug Profile 67
Product Description 67
Mechanism Of Action 67
R&D Progress 67
Small Molecule to Target Bacterial Cell Wall for Gonorrhoea and Tuberculosis - Drug Profile 68
Product Description 68
Mechanism Of Action 68
R&D Progress 68
Small Molecules for Multi-Drug Resistant Gram-Positive and Gram-Negative Bacterial Infections - Drug Profile 69
Product Description 69
Mechanism Of Action 69
R&D Progress 69
Small Molecules to Inhibit DNA Gyrase for Neisseria Gonorrhoeae Infections - Drug Profile 70
Product Description 70
Mechanism Of Action 70
R&D Progress 70
Small Molecules to Inhibit PBP2 for Neisseria Gonorrhoeae Infections - Drug Profile 71
Product Description 71
Mechanism Of Action 71
R&D Progress 71
Small Molecules to Inhibit Tubulin for Oncology and Neisseria Gonorrhoeae Infections - Drug Profile 72
Product Description 72
Mechanism Of Action 72
R&D Progress 72
solithromycin - Drug Profile 73
Product Description 73
Mechanism Of Action 73
R&D Progress 73
VT-12008911 - Drug Profile 85
Product Description 85
Mechanism Of Action 85
R&D Progress 85
Neisseria gonorrhoeae Infections - Dormant Projects 86
Neisseria gonorrhoeae Infections - Discontinued Products 87
Neisseria gonorrhoeae Infections - Product Development Milestones 88
Featured News & Press Releases 88
Dec 22, 2015: Cempra Enters Into a CRADA With the NIAID and Expands the Phase 3 Solithromycin Clinical Trial in Urogenital Gonorrhea to Include Additional Female Patients and Adolescents 88
Sep 10, 2015: Cempra to Present Data From Antibiotic Drug Solithromycin at ICAAC/ICC 2015 Meeting 88
Nov 19, 2014: Cempra to Receive BARDA Funding for 1b and Start-Up of Phase 2/3 Solithromycin Pediatric Studies 90
Sep 09, 2014: Durata Therapeutics Presented Data at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) 90
Aug 12, 2014: Cempra Initiates Phase 3 Clinical Trial in Patients With Uncomplicated Gonorrhea Infection 92
Apr 26, 2013: Cempra To Present Data On Solithromycin's Potential Against Urogenital Infections And Multidrug-Resistant Pathogens At ECCMID 92
Aug 08, 2012: BioDiem Receives European Patent For Antimicrobial Compound BDM-I 94
Mar 31, 2012: Cempra's Solithromycin Demonstrates In Vitro Activity Against Antibiotic-Resistant Neisseria Gonorrhoeae Isolates 94
Appendix 97
Methodology 97
Coverage 97
Secondary Research 97
Primary Research 97
Expert Panel Validation 97
Contact Us 97
Disclaimer 98
List of Tables
Number of Products under Development for Neisseria gonorrhoeae Infections, H2 2016 9
Number of Products under Development for Neisseria gonorrhoeae Infections - Comparative Analysis, H2 2016 10
Number of Products under Development by Companies, H2 2016 11
Number of Products under Investigation by Universities/Institutes, H2 2016 12
Comparative Analysis by Late Stage Development, H2 2016 13
Comparative Analysis by Clinical Stage Development, H2 2016 14
Comparative Analysis by Early Stage Development, H2 2016 15
Products under Development by Companies, H2 2016 16
Products under Investigation by Universities/Institutes, H2 2016 17
Neisseria gonorrhoeae Infections - Pipeline by Allergan Plc, H2 2016 18
Neisseria gonorrhoeae Infections - Pipeline by BioDiem Ltd, H2 2016 19
Neisseria gonorrhoeae Infections - Pipeline by Biolytics Pharma, H2 2016 20
Neisseria gonorrhoeae Infections - Pipeline by Debiopharm International SA , H2 2016 21
Neisseria gonorrhoeae Infections - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 22
Neisseria gonorrhoeae Infections - Pipeline by GlaxoSmithKline Plc, H2 2016 23
Neisseria gonorrhoeae Infections - Pipeline by Merck & Co., Inc., H2 2016 24
Neisseria gonorrhoeae Infections - Pipeline by Paratek Pharmaceuticals, Inc., H2 2016 25
Neisseria gonorrhoeae Infections - Pipeline by Recce Pty Ltd, H2 2016 26
Neisseria gonorrhoeae Infections - Pipeline by Redx Pharma Plc, H2 2016 27
Neisseria gonorrhoeae Infections - Pipeline by Sarepta Therapeutics, Inc., H2 2016 28
Neisseria gonorrhoeae Infections - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H2 2016 29
Assessment by Monotherapy Products, H2 2016 30
Number of Products by Stage and Target, H2 2016 32
Number of Products by Stage and Mechanism of Action, H2 2016 34
Number of Products by Stage and Route of Administration, H2 2016 36
Number of Products by Stage and Molecule Type, H2 2016 38
Neisseria gonorrhoeae Infections - Dormant Projects, H2 2016 86
Neisseria gonorrhoeae Infections - Discontinued Products, H2 2016 87
List of Figures
Number of Products under Development for Neisseria gonorrhoeae Infections, H2 2016 9
Number of Products under Development for Neisseria gonorrhoeae Infections - Comparative Analysis, H2 2016 10
Number of Products under Development by Companies, H2 2016 11
Number of Products under Investigation by Universities/Institutes, H2 2016 12
Comparative Analysis by Early Stage Products, H2 2016 15
Assessment by Monotherapy Products, H2 2016 30
Number of Products by Top 10 Targets, H2 2016 31
Number of Products by Stage and Top 10 Targets, H2 2016 31
Number of Products by Top 10 Mechanism of Actions, H2 2016 33
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 33
Number of Products by Routes of Administration, H2 2016 35
Number of Products by Stage and Routes of Administration, H2 2016 35
Number of Products by Molecule Types, H2 2016 37
Number of Products by Stage and Molecule Types, H2 2016 37
